Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

The effects of oxygen concentration on cell death, anti-oxidant transcription, acute inflammation, and cell proliferation in precision-cut lung slices.

Ruigrok MJR, Tomar J, Frijlink HW, Melgert BN, Hinrichs WLJ, Olinga P.

Sci Rep. 2019 Nov 7;9(1):16239. doi: 10.1038/s41598-019-52813-2.

2.

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study.

Beugeling M, Amssoms K, Cox F, De Clerck B, Van Gulck E, Verwoerd JA, Kraus G, Roymans D, Baert L, Frijlink HW, Hinrichs WLJ.

Pharmaceutics. 2019 Oct 3;11(10). pii: E510. doi: 10.3390/pharmaceutics11100510.

3.

Inhomogeneous Distribution of Components in Solid Protein Pharmaceuticals: Origins, Consequences, Analysis, and Resolutions.

Nguyen KTT, Frijlink HW, Hinrichs WLJ.

J Pharm Sci. 2019 Oct 10. pii: S0022-3549(19)30645-8. doi: 10.1016/j.xphs.2019.10.010. [Epub ahead of print] Review.

PMID:
31606540
4.

A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers.

Hagedoorn P, Bawary W, Frijlink HW, Grasmeijer F.

J Allergy Clin Immunol Pract. 2019 Oct 5. pii: S2213-2198(19)30847-5. doi: 10.1016/j.jaip.2019.09.021. [Epub ahead of print] No abstract available.

5.

The Effect of Food on the Pharmacokinetics of Sildenafil after Single Administration of a Sublingual Testosterone and Oral Sildenafil Combination Tablet in Healthy Female Subjects.

Bloemers J, Gerritsen J, van Rooij K, de Leede L, van der Geest R, Frijlink HW, Koppeschaar HPF, Olivier B, Tuiten A.

J Sex Med. 2019 Sep;16(9):1433-1443. doi: 10.1016/j.jsxm.2019.06.015.

PMID:
31488289
6.

Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.

Weerts ZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JWT, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Keszthelyi D.

Gastroenterology. 2019 Aug 27. pii: S0016-5085(19)41246-8. doi: 10.1053/j.gastro.2019.08.026. [Epub ahead of print]

PMID:
31470006
7.

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process.

Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW.

Pharmaceutics. 2019 Aug 23;11(9). pii: E428. doi: 10.3390/pharmaceutics11090428.

8.

Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly.

Beugeling M, De Zee J, Woerdenbag HJ, Frijlink HW, Wilschut JC, Hinrichs WLJ.

Expert Rev Vaccines. 2019 Sep;18(9):935-950. doi: 10.1080/14760584.2019.1657013. Epub 2019 Aug 25.

PMID:
31446807
9.

A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass.

Yska JP, Punter RJ, Woerdenbag HJ, Emous M, Frijlink HW, Wilffert B, van Roon EN.

Eur J Hosp Pharm. 2019 May;26(3):152-156. doi: 10.1136/ejhpharm-2017-001360. Epub 2018 Feb 8.

PMID:
31428323
10.

Oromucosal films: from patient centricity to production by printing techniques.

Tian Y, Orlu M, Woerdenbag HJ, Scarpa M, Kiefer O, Kottke D, Sjöholm E, Öblom H, Sandler N, Hinrichs WLJ, Frijlink HW, Breitkreutz J, Visser JC.

Expert Opin Drug Deliv. 2019 Sep;16(9):981-993. doi: 10.1080/17425247.2019.1652595. Epub 2019 Aug 8.

PMID:
31382842
11.

Learning from Parkinson's patients: Usability of the Cyclops dry powder inhaler.

Luinstra M, Isufi V, de Jong L, Rutgers AWF, Hagedoorn P, Puttenstein J, van Laar T, Frijlink HW.

Int J Pharm. 2019 Aug 15;567:118493. doi: 10.1016/j.ijpharm.2019.118493. Epub 2019 Jul 3.

PMID:
31279054
12.

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, Steenhuis L, Hagedoorn P, de Boer A, Frijlink HW.

Ther Adv Chronic Dis. 2019 Jun 21;10:2040622319857617. doi: 10.1177/2040622319857617. eCollection 2019.

13.

Nasal gene expression changes with inhaled corticosteroid treatment in asthma.

Boudewijn IM, Lan A, Faiz A, Cox CA, Brouwer S, Schokker S, Vroegop SJ, Nawijn MC, Woodruff PG, Christenson SA, Hagedoorn P, Frijlink HW, Choy DF, Brouwer U, Wisman M, Postma DS, Fingleton J, Beasley R, van den Berge M, Guryev V.

Allergy. 2019 Jun 22. doi: 10.1111/all.13952. [Epub ahead of print] No abstract available.

PMID:
31230369
14.

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation.

Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F.

Pharmaceutics. 2019 May 13;11(5). pii: E233. doi: 10.3390/pharmaceutics11050233.

15.

Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma.

Cox CA, Boudewijn IM, Vroegop SJ, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Vonk JM, Farenhorst MP, Ten Hacken NHT, Kerstjens HAM, van den Berge M.

BMC Pulm Med. 2019 Jan 28;19(1):23. doi: 10.1186/s12890-019-0783-0.

16.

A systematic review and meta-analysis of microbial contamination of parenteral medication prepared in a clinical versus pharmacy environment.

Larmené-Beld KHM, Frijlink HW, Taxis K.

Eur J Clin Pharmacol. 2019 May;75(5):609-617. doi: 10.1007/s00228-019-02631-2. Epub 2019 Jan 25. Review.

PMID:
30683970
17.

The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor.

van Dijk F, Teekamp N, Post E, Schuppan D, Kim YO, Zuidema J, Steendam R, Klose MHM, Meier-Menches SM, Casini A, Horvatovich PL, Sijbrandi NJ, Frijlink HW, Hinrichs WLJ, Poelstra K, Beljaars L, Olinga P.

J Control Release. 2019 Feb 28;296:250-257. doi: 10.1016/j.jconrel.2018.12.039. Epub 2019 Jan 22.

18.

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.

Gafar F, Boudewijn IM, Cox CA, Vonk JM, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Postma DS, van den Berge M.

Respir Res. 2018 Dec 18;19(1):256. doi: 10.1186/s12931-018-0961-2.

19.

Identifying critical process steps to protein stability during spray drying using a vibrating mesh or a two-fluid nozzle.

Grasmeijer N, Tiraboschi V, Woerdenbag HJ, Frijlink HW, Hinrichs WLJ.

Eur J Pharm Sci. 2019 Feb 1;128:152-157. doi: 10.1016/j.ejps.2018.11.027. Epub 2018 Dec 3.

20.

Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.

Gareb B, Dijkstra G, Kosterink JGW, Frijlink HW.

Int J Pharm. 2019 Jan 10;554:366-375. doi: 10.1016/j.ijpharm.2018.11.019. Epub 2018 Nov 8.

PMID:
30414898
21.

siRNA-mediated protein knockdown in precision-cut lung slices.

Ruigrok MJR, Xian JL, Frijlink HW, Melgert BN, Hinrichs WLJ, Olinga P.

Eur J Pharm Biopharm. 2018 Dec;133:339-348. doi: 10.1016/j.ejpb.2018.11.005. Epub 2018 Nov 7.

22.

Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge.

Tomar J, Biel C, de Haan CAM, Rottier PJM, Petrovsky N, Frijlink HW, Huckriede A, Hinrichs WLJ, Peeters B.

Eur J Pharm Biopharm. 2018 Dec;133:85-95. doi: 10.1016/j.ejpb.2018.10.008. Epub 2018 Oct 9.

23.

A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.

Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, Neef C, Jonkers DMAE, Masclee AAM.

Adv Ther. 2018 Nov;35(11):1965-1978. doi: 10.1007/s12325-018-0802-1. Epub 2018 Oct 4.

PMID:
30284674
24.

Orodispersible films based on blends of trehalose and pullulan for protein delivery.

Tian Y, Visser JC, Klever JS, Woerdenbag HJ, Frijlink HW, Hinrichs WLJ.

Eur J Pharm Biopharm. 2018 Dec;133:104-111. doi: 10.1016/j.ejpb.2018.09.016. Epub 2018 Sep 29.

25.

The mechanism behind the biphasic pulsatile drug release from physically mixed poly(dl-lactic(-co-glycolic) acid)-based compacts.

Beugeling M, Grasmeijer N, Born PA, van der Meulen M, van der Kooij RS, Schwengle K, Baert L, Amssoms K, Frijlink HW, Hinrichs WLJ.

Int J Pharm. 2018 Nov 15;551(1-2):195-202. doi: 10.1016/j.ijpharm.2018.09.025. Epub 2018 Sep 14.

26.

Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.

Tomar J, Patil HP, Bracho G, Tonnis WF, Frijlink HW, Petrovsky N, Vanbever R, Huckriede A, Hinrichs WLJ.

J Control Release. 2018 Oct 28;288:199-211. doi: 10.1016/j.jconrel.2018.09.006. Epub 2018 Sep 12.

27.

Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.

Amssoms K, Born PA, Beugeling M, De Clerck B, Van Gulck E, Hinrichs WLJ, Frijlink HW, Grasmeijer N, Kraus G, Sutmuller R, Simmen K, Baert L.

PLoS One. 2018 Aug 30;13(8):e0202961. doi: 10.1371/journal.pone.0202961. eCollection 2018.

28.

Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization.

Kanojia G, Raeven RHM, van der Maas L, Bindels THE, van Riet E, Metz B, Soema PC, Ten Have R, Frijlink HW, Amorij JP, Kersten GFA.

J Control Release. 2018 Sep 28;286:167-178. doi: 10.1016/j.jconrel.2018.07.035. Epub 2018 Jul 24.

29.

Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial.

Tuiten A, Michiels F, Böcker KB, Höhle D, van Honk J, de Lange RP, van Rooij K, Kessels R, Bloemers J, Gerritsen J, Janssen P, de Leede L, Meyer JJ, Everaerd W, Frijlink HW, Koppeschaar HP, Olivier B, Pfaus JG.

Womens Health (Lond). 2018 Jan-Dec;14:1745506518788970. doi: 10.1177/1745506518788970.

30.

Challenges for pulmonary delivery of high powder doses.

Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F.

Int J Pharm. 2018 Sep 5;548(1):325-336. doi: 10.1016/j.ijpharm.2018.07.008. Epub 2018 Jul 2. Review.

31.

The effect of formulation on spray dried Sabin inactivated polio vaccine.

Kanojia G, Ten Have R, Brugmans D, Soema PC, Frijlink HW, Amorij JP, Kersten G.

Eur J Pharm Biopharm. 2018 Aug;129:21-29. doi: 10.1016/j.ejpb.2018.05.021. Epub 2018 May 19.

32.

Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.

Bhide Y, Tomar J, Dong W, de Vries-Idema J, Frijlink HW, Huckriede A, Hinrichs WLJ.

Drug Deliv. 2018 Nov;25(1):533-545. doi: 10.1080/10717544.2018.1435748.

33.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

34.

Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs.

Lexmond AJ, Singh D, Frijlink HW, Clarke GW, Page CP, Forbes B, van den Berge M.

Pulm Pharmacol Ther. 2018 Apr;49:27-35. doi: 10.1016/j.pupt.2018.01.004. Epub 2018 Jan 10. Review.

35.

Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.

Tuiten A, van Rooij K, Bloemers J, Eisenegger C, van Honk J, Kessels R, Kingsberg S, Derogatis LR, de Leede L, Gerritsen J, Koppeschaar HPF, Olivier B, Everaerd W, Frijlink HW, Höhle D, de Lange RPJ, Böcker KBE, Pfaus JG.

J Sex Med. 2018 Feb;15(2):201-216. doi: 10.1016/j.jsxm.2017.11.226. Epub 2017 Dec 27.

36.

Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.

Cox CA, Boudewijn IM, Vroegop SJ, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Vonk JM, Farenhorst MP, Ten Hacken NHT, Kerstjens HAM, Postma DS, van den Berge M.

Respir Med. 2017 Sep;130:35-42. doi: 10.1016/j.rmed.2017.07.005. Epub 2017 Jul 8.

37.

Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver.

van Dijk F, Teekamp N, Beljaars L, Post E, Zuidema J, Steendam R, Kim YO, Frijlink HW, Schuppan D, Poelstra K, Hinrichs WLJ, Olinga P.

J Control Release. 2018 Jan 10;269:258-265. doi: 10.1016/j.jconrel.2017.11.029. Epub 2017 Nov 21.

38.

Efficient production of solid dispersions by spray drying solutions of high solid content using a 3-fluid nozzle.

Kauppinen A, Broekhuis J, Grasmeijer N, Tonnis W, Ketolainen J, Frijlink HW, Hinrichs WLJ.

Eur J Pharm Biopharm. 2018 Feb;123:50-58. doi: 10.1016/j.ejpb.2017.11.009. Epub 2017 Nov 21.

39.

Targeting the small airways with dry powder adenosine: a challenging concept.

van der Wiel E, Lexmond AJ, van den Berge M, Postma DS, Hagedoorn P, Frijlink HW, Farenhorst MP, de Boer AH, Ten Hacken NHT.

Eur Clin Respir J. 2017 Sep 6;4(1):1369328. doi: 10.1080/20018525.2017.1369328. eCollection 2017.

40.

Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney.

Teekamp N, Van Dijk F, Broesder A, Evers M, Zuidema J, Steendam R, Post E, Hillebrands JL, Frijlink HW, Poelstra K, Beljaars L, Olinga P, Hinrichs WLJ.

Int J Pharm. 2017 Dec 20;534(1-2):229-236. doi: 10.1016/j.ijpharm.2017.09.072. Epub 2017 Oct 14.

41.

Addition of Pullulan to Trehalose Glasses Improves the Stability of β-Galactosidase at High Moisture Conditions.

Teekamp N, Tian Y, Visser JC, Olinga P, Frijlink HW, Woerdenbag HJ, Hinrichs WLJ.

Carbohydr Polym. 2017 Nov 15;176:374-380. doi: 10.1016/j.carbpol.2017.08.084. Epub 2017 Aug 24.

42.

siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney.

Ruigrok MJR, Maggan N, Willaert D, Frijlink HW, Melgert BN, Olinga P, Hinrichs WLJ.

AAPS J. 2017 Nov;19(6):1855-1863. doi: 10.1208/s12248-017-0136-y. Epub 2017 Sep 11.

PMID:
28895093
43.

Thermal Gradient Mid- and Far-Infrared Spectroscopy as Tools for Characterization of Protein Carbohydrate Lyophilizates.

Mensink MA, Šibík J, Frijlink HW, van der Voort Maarschalk K, Hinrichs WLJ, Zeitler JA.

Mol Pharm. 2017 Oct 2;14(10):3550-3557. doi: 10.1021/acs.molpharmaceut.7b00568. Epub 2017 Sep 15.

44.

Prerequisites for a dry powder inhaler for children with cystic fibrosis.

Lexmond AJ, Hagedoorn P, Frijlink HW, Rottier BL, de Boer AH.

PLoS One. 2017 Aug 11;12(8):e0183130. doi: 10.1371/journal.pone.0183130. eCollection 2017.

45.

Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.

Patil HP, Herrera Rodriguez J, de Vries-Idema J, Meijerhof T, Frijlink HW, Hinrichs WLJ, Huckriede A.

Vaccines (Basel). 2017 Jul 27;5(3). pii: E19. doi: 10.3390/vaccines5030019.

46.

Increased drug load and polymer compatibility of bilayered orodispersible films.

Carolina Visser J, Weggemans OAF, Boosman RJ, Loos KU, Frijlink HW, Woerdenbag HJ.

Eur J Pharm Sci. 2017 Sep 30;107:183-190. doi: 10.1016/j.ejps.2017.07.010. Epub 2017 Jul 12.

PMID:
28709911
47.

Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate.

Lexmond AJ, Boudewijn IM, Hagedoorn P, Schokker S, Cox CA, Vonk JM, Ten Hacken NHT, Frijlink HW, Vroegop SJ, van den Berge M.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):391-394. doi: 10.1164/rccm.201704-0715LE. No abstract available.

PMID:
28650210
48.

Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.

van Doorn E, Pleguezuelos O, Liu H, Fernandez A, Bannister R, Stoloff G, Oftung F, Norley S, Huckriede A, Frijlink HW, Hak E.

BMC Infect Dis. 2017 Apr 4;17(1):241. doi: 10.1186/s12879-017-2341-9.

49.

Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.

van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, Frijlink HW, Hak E.

Medicine (Baltimore). 2017 Mar;96(11):e6339. doi: 10.1097/MD.0000000000006339.

50.

Ready-to-use parenteral amiodarone: a feasibility study towards a long-term stable product formulation.

Jacobs MS, Luinstra M, Moes JR, Chan TCY, Minovic I, Frijlink HW, Woerdenbag HJ.

Eur J Hosp Pharm. 2017 Mar;24(2):110-114. doi: 10.1136/ejhpharm-2015-000860. Epub 2016 Apr 13.

Supplemental Content

Loading ...
Support Center